Chao Family Comprehensive Cancer Center Clinical Trials: Melanoma Prevention
Protocol#	Principal Investigator	Title
UCI 06-06	Linden	A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

 

A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
This study is actively recruiting participants at:
University of California, Irvine
University of Utah
University of South Florida

 

The purpose of this study is to examine the safety and efficacy of Lovastatin as an agent that can protect against the development of skin cancer (melanoma). Lovastatin will be evaluated for its potential to alter cells within atypical nevi (moles) and potentially reverse the cells’ ability to progress to melanoma.

The study targets individuals over the age of 18 with a history of melanoma and at least 2 abnormal moles on his/her back. This study is funded by the National Cancer Institute as part of the Southern California Chemoprevention Consortia. It is being conducted by Kenneth Linden, MD at the University of California, Irvine (UCI), Sancy Leachman, MD, PhD at the University of Utah, and Vernon Sondak, MD at the University of South Florida, who are recruiting participants for this study.

Chao Family Comprehensive Cancer Center
101 The City Drive
Bldg. 23; Route 81
Orange, CA 92868
For further information, call (714) 456-3592.

Comments & Questions: Privacy & Legal Notice
Copyright Inquiries